{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:12:06Z","timestamp":1790809926605,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jtho.2021.08.764","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T14:50:20Z","timestamp":1633013420000},"page":"76-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC"],"prefix":"10.1016","volume":"17","author":[{"given":"Mohamed Mahde","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Scheffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Merkelbach-Bruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Hans","family":"Scheel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Buettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2021.08.764_bib1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtho.2021.08.764_bib2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jtho.2021.08.764_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","article-title":"p53: 800 million years of evolution and 40 years of discovery","volume":"20","author":"Levine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2021.08.764_bib4","first-page":"4855","article-title":"Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis","volume":"54","author":"Greenblatt","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/342705a0","article-title":"Mutations in the p53 gene occur in diverse human tumour types","volume":"342","author":"Nigro","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2021.08.764_bib6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53\u00a0mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.jtho.2021.08.764_bib7","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.molcel.2018.08.013","article-title":"A\u00a0systematic p53 mutation library links differential functional impact to cancer mutation pattern and evolutionary conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol Cell"},{"key":"10.1016\/j.jtho.2021.08.764_bib9","doi-asserted-by":"crossref","first-page":"64910","DOI":"10.18632\/oncotarget.11912","article-title":"Immunohistochemical correlates of TP53 somatic mutations in cancer","volume":"7","author":"Murny\u00e1k","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2021.08.764_bib10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain-of-function in cancer","volume":"2","author":"Oren","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jtho.2021.08.764_bib11","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1038\/sj.onc.1210294","article-title":"Transcription regulation by mutant p53","volume":"26","author":"Weisz","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jtho.2021.08.764_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2021.08.764_bib13","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1073\/pnas.1431692100","article-title":"Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis","volume":"100","author":"Kato","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2021.08.764_bib14","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","article-title":"Mutational processes shape the landscape of TP53 mutations in human cancer","volume":"50","author":"Giacomelli","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.08.764_bib15","doi-asserted-by":"crossref","first-page":"a001016","DOI":"10.1101\/cshperspect.a001016","article-title":"Clinical outcomes and correlates of TP53 mutations and cancer","volume":"2","author":"Robles","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jtho.2021.08.764_bib16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3892\/mco.2016.1057","article-title":"TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: evidence from a meta-analysis","volume":"5","author":"Gu","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib17","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1200\/JCO.2007.12.6953","article-title":"Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer","volume":"25","author":"Tsao","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib18","article-title":"Influence of TP53 mutation on survival in patients with advanced EGFR-mutant non-small-cell lung cancer","volume":"2018","author":"Aggarwal","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib19","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1200\/JCO.2016.71.2893","article-title":"Pooled analysis of the prognostic and predictive effects of TP53 comutation status combined with KRAS or EGFR mutation in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy","volume":"35","author":"Shepherd","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib20","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1158\/1078-0432.CCR-13-2391","article-title":"Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer","volume":"20","author":"Molina-Vila","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/JTO.0b013e3181a4b8fb","article-title":"Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer","volume":"4","author":"Custodio","year":"2009","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2016.02.002","article-title":"Prognostic and predictive effect of TP53 mutations in patients with non-small cell lung cancer from adjuvant cisplatin-based therapy randomized trials: a LACE-bio pooled analysis","volume":"11","author":"Ma","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib23","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2021.08.764_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","article-title":"Role of KEAP1\/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung cancer","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib25","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1158\/1078-0432.CCR-20-1073","article-title":"Plasma tumor mutation burden and response to pembrolizumab\u2014response","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib26","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-000706","article-title":"STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort","volume":"5","author":"Papillon-Cavanagh","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.jtho.2021.08.764_bib28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/13510002.2017.1416773","article-title":"A\u00a0systematic review of p53 regulation of oxidative stress in skeletal muscle","volume":"23","author":"Beyfuss","year":"2018","journal-title":"Redox Rep"},{"key":"10.1016\/j.jtho.2021.08.764_bib29","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","article-title":"Mutations in the KEAP1-NFE2L2 pathway define a molecular subset of rapidly progressing lung adenocarcinoma","volume":"14","author":"Goeman","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib30","doi-asserted-by":"crossref","first-page":"20508","DOI":"10.18632\/oncotarget.24974","article-title":"Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells","volume":"9","author":"Lisek","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtho.2021.08.764_bib31","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1089\/ars.2012.4674","article-title":"Does Nrf2 contribute to p53-mediated control of cell survival and death?","volume":"17","author":"Chen","year":"2012","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.jtho.2021.08.764_bib32","doi-asserted-by":"crossref","first-page":"39776","DOI":"10.1074\/jbc.M605707200","article-title":"p53 suppresses the Nrf2-dependent transcription of antioxidant response genes","volume":"281","author":"Faraonio","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"suppl 3","key":"10.1016\/j.jtho.2021.08.764_bib33","doi-asserted-by":"crossref","first-page":"iii25","DOI":"10.1093\/annonc\/mdw303","article-title":"ALK evaluation in the world of multiplex testing: Network Genomic Medicine (NGM): the Cologne model for implementing personalised oncology","volume":"27","author":"Heydt","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12885-020-06920-3","article-title":"Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors","volume":"20","author":"Wagener-Ryczek","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtho.2021.08.764_bib35","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/JTO.0000000000000570","article-title":"Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients","volume":"10","author":"K\u00f6nig","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib36","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2021.08.764_bib37","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.jtho.2021.08.764_bib38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.08.764_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A\u00a0note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtho.2021.08.764_bib40","first-page":"1210","article-title":"Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy","volume":"20","author":"Kelsey","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jtho.2021.08.764_bib41","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1158\/1078-0432.CCR-11-0183","article-title":"Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma","volume":"17","author":"Lindenbergh-van der Plas","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib42","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.17929","article-title":"TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions","volume":"5","author":"Shirole","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.jtho.2021.08.764_bib43","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000055315","article-title":"Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance","volume":"60","author":"Suzuki","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.jtho.2021.08.764_bib44","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1101\/gr.176214.114","article-title":"A\u00a0formal perturbation equation between genotype and phenotype determines the evolutionary action of protein-coding variations on fitness","volume":"24","author":"Katsonis","year":"2014","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/jso.21520","article-title":"Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer","volume":"101","author":"Takahashi","year":"2010","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib46","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","article-title":"Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features","volume":"16","author":"Solis","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2021.08.764_bib47","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2021.08.764_bib48","article-title":"Impact of KRAS and TP53 co-mutations on outcomes after first-line systemic therapy among patients with STK11-mutated advanced non-small-cell lung cancer","volume":"3","author":"Bange","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12964-020-00568-z","article-title":"Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1\/NRF2 pathway activation","volume":"18","author":"Gong","year":"2020","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.jtho.2021.08.764_bib50","first-page":"5578","article-title":"Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species","volume":"125","author":"Kalo","year":"2012","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.jtho.2021.08.764_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.17062","article-title":"Comparison of conventional TNM and novel TNMB staging systems for non-small cell lung cancer","volume":"2","author":"Haro","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtho.2021.08.764_bib52","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0140-6736(11)61941-7","article-title":"A\u00a0practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies","volume":"379","author":"Kratz","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.08.764_bib53","doi-asserted-by":"crossref","first-page":"794","DOI":"10.5858\/arpa.2018-0087-ED","article-title":"Molecular testing for early lung cancer","volume":"142","author":"Altorki","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtho.2021.08.764_bib54","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib55","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.2017.022251","article-title":"Adjuvant systemic therapy and adjuvant radiation therapy for stages I to IIIA resectable non-small-cell lung cancers: American Society of Clinical Oncology\/Cancer Care Ontario Clinical Practice Guideline Update Summary","volume":"13","author":"Kris","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtho.2021.08.764_bib56","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib57","doi-asserted-by":"crossref","first-page":"595187","DOI":"10.3389\/fonc.2020.595187","article-title":"Mutant p53 in cancer progression and targeted therapies","volume":"10","author":"Zhu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib58","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/febs.13948","article-title":"Targeting mutant p53 in cancer: a long road to precision therapy","volume":"284","author":"Mantovani","year":"2017","journal-title":"FEBS J"},{"key":"10.1016\/j.jtho.2021.08.764_bib59","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ejca.2017.06.023","article-title":"Mutant p53 as a target for cancer treatment","volume":"83","author":"Duffy","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtho.2021.08.764_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2021.08.764_bib61","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.18.01074","article-title":"Comparison of population-based observational studies with randomized trials in oncology","volume":"37","author":"Soni","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2021.08.764_bib62","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2021.08.764_bib63","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1002\/sim.7343","article-title":"How serious is bias in effect estimation in randomised trials with survival data given risk heterogeneity and informative censoring?","volume":"36","author":"McNamee","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jtho.2021.08.764_bib64","doi-asserted-by":"crossref","first-page":"a000927","DOI":"10.1101\/cshperspect.a000927","article-title":"The isoforms of the p53 protein","volume":"2","author":"Khoury","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.jtho.2021.08.764_bib65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/cancers10090288","article-title":"p53 isoforms and their implications in cancer","volume":"10","author":"Vieler","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtho.2021.08.764_bib66","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421031877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086421031877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:48:21Z","timestamp":1761562101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086421031877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1556086421031877"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2021.08.764","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Analysis of TP53 and KEAP1 Mutations and Their Impact on Survival in Localized- and Advanced-Stage NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2021.08.764","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}